title: Virtual HDR CyberKnife SBRT for Localized Prostatic Carcinoma: 5-Year Disease-Free Survival and Toxicity Observations.
abstract: OBJECTIVE
  Prostate stereotactic body radiotherapy (SBRT) may substantially recapitulate the dose distribution of high-dose-rate (HDR) brachytherapy, representing an externally delivered "Virtual HDR" treatment method. Herein, we present 5-year outcomes from a cohort of consecutively treated virtual HDR SBRT prostate cancer patients.
  
  
  METHODS
  Seventy-nine patients were treated from 2006 to 2009, 40 low-risk, and 39 intermediate-risk, under IRB-approved clinical trial, to 38 Gy in four fractions. The planning target volume (PTV) included prostate plus a 2-mm volume expansion in all directions, with selective use of a 5-mm prostate-to-PTV expansion and proximal seminal vesicle coverage in intermediate-risk patients, to better cover potential extraprostatic disease; rectal PTV margin reduced to zero in all cases. The prescription dose covered >95% of the PTV (V100 ≥95%), with a minimum 150% PTV dose escalation to create "HDR-like" PTV dose distribution.
  
  
  RESULTS
  Median pre-SBRT PSA level of 5.6 ng/mL decreased to 0.05 ng/mL 5 years out and 0.02 ng/mL 6 years out. At least one PSA bounce was seen in 55 patients (70%) but only 3 of them subsequently relapsed, biochemical-relapse-free survival was 100 and 92% for low-risk and intermediate-risk patients, respectively, by ASTRO definition (98 and 92% by Phoenix definition). Local relapse did not occur, distant metastasis-free survival was 100 and 95% by risk-group, and disease-specific survival was 100%. Acute and late grade 2 GU toxicity incidence was 10 and 9%, respectively; with 6% late grade 3 GU toxicity. Acute urinary retention did not occur. Acute and late grade 2 GI toxicity was 0 and 1%, respectively, with no grade 3 or higher toxicity. Of patient's potent pre-SBRT, 65% remained so at 5 years.
  
  
  CONCLUSIONS
  Virtual HDR prostate SBRT creates a very low PSA nadir, a high rate of 5-year disease-free survival and an acceptable toxicity incidence, with results closely resembling those reported post-HDR brachytherapy.
authors.affiliation: Division of Genesis Healthcare Partners Inc., CyberKnife Centers of San Diego Inc. , San Diego, CA , USA.
authors.forename: Donald Blake
authors.initials: DB
authors.lastname: Fuller
authors.affiliation: Division of Genesis Healthcare Partners Inc., Coast Urology Medical Group Inc. , La Jolla, CA , USA.
authors.forename: John
authors.initials: J
authors.lastname: Naitoh
authors.affiliation: Division of Genesis Healthcare Partners Inc., CyberKnife Centers of San Diego Inc. , San Diego, CA , USA.
authors.forename: George
authors.initials: G
authors.lastname: Mardirossian
keywords: CyberKnife; HDR; brachytherapy; dosimetry; image guided; prostate cancer; stereotactic body radiotherapy